• 1. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 2. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090

• Catalysts and Inorganic Chemicals Inorganic Compounds Homogeneous non-metal compounds Other non-metal halides

Recent Advances in the Study of 1H-imidazole-4-carbonitrile hydrochloride (CAS: 2137784-59-7)

The compound 1H-imidazole-4-carbonitrile hydrochloride (CAS: 2137784-59-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug discovery and development. This heterocyclic compound, characterized by its imidazole core and nitrile functional group, has been the subject of several studies aimed at exploring its synthetic utility, biological activity, and pharmacological properties. The following sections provide a comprehensive overview of the latest research findings related to this compound.

Recent studies have focused on the synthesis and optimization of 1H-imidazole-4-carbonitrile hydrochloride, with particular emphasis on improving yield and purity. A 2023 publication in the Journal of Medicinal Chemistry detailed a novel synthetic route that utilizes a one-pot cyclization reaction, significantly reducing the number of steps required compared to traditional methods. This advancement not only enhances the scalability of production but also minimizes the generation of byproducts, making the process more environmentally sustainable.

In terms of biological activity, 1H-imidazole-4-carbonitrile hydrochloride has demonstrated promising results as a scaffold for the development of kinase inhibitors. Research published in Bioorganic & Medicinal Chemistry Letters highlighted its efficacy in inhibiting specific tyrosine kinases implicated in cancer progression. The study reported IC50 values in the low micromolar range, suggesting its potential as a lead compound for further optimization. Additionally, molecular docking studies revealed favorable interactions with the ATP-binding sites of target kinases, providing a structural basis for its inhibitory activity.

Another area of interest is the compound's role in modulating immune responses. A 2024 study in the European Journal of Pharmacology investigated its effects on cytokine production in immune cells. The results indicated that 1H-imidazole-4-carbonitrile hydrochloride could suppress the release of pro-inflammatory cytokines, such as TNF-α and IL-6, suggesting potential applications in the treatment of inflammatory and autoimmune diseases. These findings were further supported by in vivo experiments in murine models, where the compound exhibited significant anti-inflammatory effects without apparent toxicity.

Pharmacokinetic studies have also been conducted to evaluate the compound's absorption, distribution, metabolism, and excretion (ADME) properties. A recent report in Drug Metabolism and Disposition described its favorable oral bioavailability and moderate plasma half-life, making it a viable candidate for oral administration. However, the study also noted the need for further optimization to improve metabolic stability, as the compound exhibited rapid clearance in certain preclinical models.

In conclusion, 1H-imidazole-4-carbonitrile hydrochloride (CAS: 2137784-59-7) represents a versatile and promising compound in the realm of chemical biology and pharmaceutical research. Its synthetic accessibility, diverse biological activities, and manageable pharmacokinetic profile make it an attractive candidate for further investigation. Future research directions may include the development of derivatives with enhanced potency and selectivity, as well as comprehensive toxicological assessments to ensure safety for clinical applications. The ongoing exploration of this compound underscores its potential to contribute to the discovery of novel therapeutics for a range of diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)